Adrenaline crisis kits

·         Supply of adrenal crisis kits V1.1

Diabetes

·         Levemir discontinuation guidance (November 2025) V1.1

·         Diabetes and Frailty guidance June 2026

·         Summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults (last updated May 2026)

·         NICE NG28 Type 2 diabetes in adults: management

·         NICE NG17 Type 1 diabetes in adults: diagnosis and management

·         NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management

·         Blood Glucose (finger prick) and Ketone Monitoring in Adults 2026

·         Lancet factsheet V4.1 (2025)

·         Needles for Pen Injectors factsheet V4 (2024)

·         Semaglutide (Ozempic) setting pre-set quantities in GP practice systems to prevent overprescribing

Diabetes patient leaflets

·         GLP-1 and Type 2 Diabetes: Making the Most of your Meds (Coastal PCN APC Nov 25)

Sharps Bins disposal

Cornwall Council: sharps bins collections information or 0300 1234 141

Isles of Scilly Council: For advice and disposal arrangements please contact St Mary's Hospital on 01720 422392

Tirzepatide (Mounjaro): weight loss

This information aims to provide information relating to tirzepatide (Mounjaro) as it is released from NHSE and in line with local implementation plans.

Introduction

Tirzepatide (Mounjaro) is a weight loss drug that, up to now, has only been prescribed for people with type 2 diabetes.

NICE published guidance on 23 December 2024 recommending that tripeptide (Mounjaro) be considered a treatment option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity.

Tirzepatide (Mounjaro) criteria

Initially, because of the impact on services, NICE agreed that NHS England should publish criteria for the priority cohorts for Tirzepatide (Mounjaro).

Those priority cohorts are:

The Qualifying Co-morbidities are as follows:

Over time, these cohorts will be expanded to include the full criteria for tirzepatide (Mounjaro) which are:

People over the age of 18 who have a body mass index (BMI) of 35 or over (or a BMI of 32.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds, as they are at a higher risk of medical problems at a lower BMI) and one of the above weight-related co-morbidities.

Weight loss injections are not suitable for patients who:

• Have previously had weight loss surgery.
• Are not engaging in NHS wrap-around care.

Please also see the product SmPC for a complete list of prescribing cautions and contraindications.

Wrap-around care

The NICE TA1026 mandates provision of wrap-around care alongside the prescribing of tirzepatide (Mounjaro). NHSE expects that this will incorporate nutritional and dietetic advice as a minimum and access to behavioural change components, as a mandatory requirement to access treatment.

Further information

BMA: Tirzepatide (Mounjaro) for weight management in General Practice

Private prescribing

Online purchase

The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) warns against buying weight loss medicines without a prescription.